Literature DB >> 9153241

A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate.

O Hashimoto1, T Nakamura, H Shoji, S Shimasaki, Y Hayashi, H Sugino.   

Abstract

There are two types of the activin-binding protein follistatin (FS), FS-288 and FS-315. These result from alternative splicing of mRNA. FS-288 exhibits high affinity for cell-surface heparan sulfate proteoglycans, whereas FS-315 shows low affinity. To understand the physiological role of cell-associated FS, we investigated the binding of activin to cell-associated FS and its behavior on the cell surface using primary cultured rat pituitary cells. Affinity cross-linking experiments using 125I-activin A demonstrated that activin bound to rat pituitary cells via FS as well as to their receptors on the cell surface. FS-288 promoted the binding of activin A to the cell surface more markedly than FS-315. When the cells were incubated with 125I-activin A in the presence of FS-288, significant degradation of activin A was observed, and this was dependent on the FS-288 concentration. This activin degradation was abolished by heparan sulfate, chloroquine, and several lysosomal enzyme inhibitors. Moreover, FS-288 stimulated cellular uptake of activin A, whereas chloroquine suppressed lysosomal degradation following internalization, as demonstrated by microscopic autoradiography. These results suggest that cell-associated FS-288 accelerates the uptake of activin A into pituitary cells, leading to increased degradation by lysosomal enzymes, and thus plays a role in the activin clearance system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153241     DOI: 10.1074/jbc.272.21.13835

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Rapid, efficient isolation of murine gonadotropes and their use in revealing control of follicle-stimulating hormone by paracrine pituitary factors.

Authors:  Joyce C Wu; Pei Su; Nedal W Safwat; Joseph Sebastian; William L Miller
Journal:  Endocrinology       Date:  2004-08-19       Impact factor: 4.736

2.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 3.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 4.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

Review 5.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

6.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

7.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

8.  Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.

Authors:  Chandramohan Kattamuri; Kristof Nolan; Thomas B Thompson
Journal:  Biochem J       Date:  2017-03-08       Impact factor: 3.857

9.  Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization.

Authors:  Wan-Jong Kuo; Michelle A Digman; Arthur D Lander
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

10.  Cleavages within the prodomain direct intracellular trafficking and degradation of mature bone morphogenetic protein-4.

Authors:  Catherine Degnin; François Jean; Gary Thomas; Jan L Christian
Journal:  Mol Biol Cell       Date:  2004-09-08       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.